PEMGARDA Added to NCCN Guidelines for B-Cell Lymphomas
May 23, 2025
Invivyd, announced that PEMGARDA (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer NetworkClinical Practice Guidelines in Oncology for B-Cell Lymphomas. NCCN